AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35715803 — intervention group
Group type: EXPERIMENTAL
Intervention: GMZ2 vaccine (two formulations: aluminum Alhydrogel and CAF01)
Number of subjects: 50
Study 35715803 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (Verorab)
Number of subjects: 50
Study 33183970 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/day for 1 year
Number of subjects: 2840
Study 33183970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2840
Study 35178136 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy group (PT) received ELF EMF and LED therapy in addition to Paracetamol and NSAID-ibuprofen.
Number of subjects: 32
Study 35178136 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received Paracetamol and NSAID-ibuprofen only.
Number of subjects: 32
Study 34162641 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-assisted cognitive behavioural therapy (ICBT) with telephone coaching
Number of subjects: 0
Study 34162641 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 0
Study 32108355 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-1 therapy
Number of subjects: 17
Study 32108355 — intervention group
Group type: COMPARATOR
Intervention: Control (glucocorticoid therapy only)
Number of subjects: 17
Study 36294115 — intervention group
Group type: EXPERIMENTAL
Intervention: Cha‐cha dance training (CTG)
Number of subjects: 40
Study 36294115 — intervention group
Group type: COMPARATOR
Intervention: Control group (CONG)
Number of subjects: 40
Study 32865325 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM NiTi retainer
Number of subjects: 60
Study 32865325 — intervention group
Group type: COMPARATOR
Intervention: Multi‐stranded stainless steel retainer
Number of subjects: 60
Study 32865325 — intervention group
Group type: COMPARATOR
Intervention: Single‐stranded nickel‐free titanium retainer
Number of subjects: 60
Study 32865325 — intervention group
Group type: COMPARATOR
Intervention: Vacuum‐formed removable retainer
Number of subjects: 60
Study 34401935 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drain (group A)
Number of subjects: 84
Study 34401935 — intervention group
Group type: COMPARATOR
Intervention: No closed suction drain (group B)
Number of subjects: 84
Study 34445035 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g·day−1 NZBC extract
Number of subjects: 27
Study 36446063 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention for COVID-19 prevention
Number of subjects: 0
Study 36446063 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33744041 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 18
Study 33744041 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Number of subjects: 18
Study 33744041 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal
Number of subjects: 18
Study 33744041 — intervention group
Group type: COMPARATOR
Intervention: All meals
Number of subjects: 18
Study 33346375 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan/rosuvastatin fixed-dose combination (FDC)
Number of subjects: 150
Study 33346375 — intervention group
Group type: COMPARATOR
Intervention: Usual regimen (separate angiotensin receptor blockers and statins)
Number of subjects: 150
Study 35978350 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengyinnaotong Capsule plus routine basic treatment
Number of subjects: 270
Study 35978350 — intervention group
Group type: COMPARATOR
Intervention: Routine basic treatment
Number of subjects: 270
Study 33947825 — intervention group
Group type: EXPERIMENTAL
Intervention: Graston technique plus exercise program
Number of subjects: 60
Study 33947825 — intervention group
Group type: COMPARATOR
Intervention: Exercise program only
Number of subjects: 60
Study 32249446 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal regeneration (PR)
Number of subjects: 50
Study 32249446 — intervention group
Group type: COMPARATOR
Intervention: Tooth extraction and replacement (TER)
Number of subjects: 50
Study 35235823 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS format - text
Number of subjects: 220
Study 35235823 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS format - text table
Number of subjects: 220
Study 35235823 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS format - text graphs
Number of subjects: 220
Study 35235823 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS format - tailored to subject's graph literacy score
Number of subjects: 220
Study 34376218 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 192
Study 34376218 — intervention group
Group type: COMPARATOR
Intervention: No beta-blocker therapy (Control)
Number of subjects: 192
Study 32157334 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 1360
Study 32157334 — intervention group
Group type: COMPARATOR
Intervention: Risedronate
Number of subjects: 1360
Study 36267013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheonwangbosimdan
Number of subjects: 48
Study 36267013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 34531203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 101
Study 34531203 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 101
Study 34531203 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 101
Study 33167735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus trastuzumab and chemotherapy
Number of subjects: 0
Study 33167735 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and chemotherapy
Number of subjects: 0
Study 34339669 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient‐controlled analgesia with ropivacaine CRIB
Number of subjects: 66
Study 34339669 — intervention group
Group type: COMPARATOR
Intervention: Patient‐controlled intravenous analgesia with sufentanil
Number of subjects: 66
Study 34249145 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil + Lidocaine (S + L)
Number of subjects: 130
Study 34249145 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (S)
Number of subjects: 130
Study 33216275 — intervention group
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Number of subjects: 94
Study 35777735 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine + Ketamine (BK group)
Number of subjects: 159
Study 35777735 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine + Dexmedetomidine (BD group)
Number of subjects: 159
Study 35777735 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine only (B group)
Number of subjects: 159
Study 34155966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt sulfate at 0.11 mg Co/kg dry matter (DM)
Number of subjects: 40
Study 34155966 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid at 7.2 mg/kg DM
Number of subjects: 40
Study 34155966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt sulfate at 0.11 mg Co/kg DM
Number of subjects: 40
Study 35999257 — intervention group
Group type: EXPERIMENTAL
Intervention: NewU (uniform with a new applied fabric treatment)
Number of subjects: 8
Study 35999257 — intervention group
Group type: COMPARATOR
Intervention: CurrU (current Army uniform)
Number of subjects: 8
Study 33462831 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg pembrolizumab every 3 weeks
Number of subjects: 0
Study 33462831 — intervention group
Group type: COMPARATOR
Intervention: Randomized dose comparison studies (KN001 B2 and D)
Number of subjects: 0
Study 33119623 — intervention group
Group type: EXPERIMENTAL
Intervention: Management decisions based on clinical vignettes for appendicitis
Number of subjects: 0
Study 33119623 — intervention group
Group type: EXPERIMENTAL
Intervention: Management decisions based on clinical vignettes for pharyngitis
Number of subjects: 0
Study 33119623 — intervention group
Group type: EXPERIMENTAL
Intervention: GP's estimated probability of disease for pharyngitis
Number of subjects: 0
Study 33119623 — intervention group
Group type: EXPERIMENTAL
Intervention: GP's estimated probability of disease for appendicitis
Number of subjects: 0
Study 33119623 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct estimation of probability of disease by GPs for appendicitis
Number of subjects: 0
Study 33119623 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct estimation of probability of disease by GPs for pharyngitis
Number of subjects: 0
Study 34836880 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week stepwise return-to-PA protocol at 72 hours post concussion
Number of subjects: 456
Study 34836880 — intervention group
Group type: COMPARATOR
Intervention: Resting until asymptomatic
Number of subjects: 456
Study 35641211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg
Number of subjects: 261
Study 35641211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 30 mg
Number of subjects: 261
Study 35641211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 mg
Number of subjects: 261
Study 35641211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 45/15 mg
Number of subjects: 261
Study 35641211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib (general)
Number of subjects: 261
Study 35641211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib (readjudication)
Number of subjects: 261
Study 33599689 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined tuberculosis susceptibility
Number of subjects: 999
Study 33599689 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐SPOT.TB positivity
Number of subjects: 999
Study 33599689 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 999
Study 32716706 — intervention group
Group type: COMPARATOR
Intervention: On-time denosumab dosing (within 4 weeks after the recommended date)
Number of subjects: 2594
Study 32716706 — intervention group
Group type: EXPERIMENTAL
Intervention: Short delay denosumab dosing (delay by 4 to 16 weeks)
Number of subjects: 2594
Study 32716706 — intervention group
Group type: EXPERIMENTAL
Intervention: Long delay denosumab dosing (delay by more than 16 weeks)
Number of subjects: 2594
Study 35456180 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Drink (ED)
Number of subjects: 27
Study 35456180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 34749668 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ALA (α-linolenic acid) levels
Number of subjects: 113937
Study 34749668 — intervention group
Group type: EXPERIMENTAL
Intervention: DPA (docosapentaenoic acid)
Number of subjects: 113937
Study 34749668 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (eicosapentaenoic acid)
Number of subjects: 113937
Study 34749668 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (docosahexaenoic acid)
Number of subjects: 113937
Study 36202666 — intervention group
Group type: EXPERIMENTAL
Intervention: THAA group
Number of subjects: 139
Study 36202666 — intervention group
Group type: COMPARATOR
Intervention: non-THAA group
Number of subjects: 139
Study 33657983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience
Number of subjects: 484
Study 33657983 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 484
Study 32444306 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 114
Study 32444306 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 114
Study 32444306 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 114
Study 35318777 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic gas filling (720 mL)
Number of subjects: 16
Study 35318777 — intervention group
Group type: COMPARATOR
Intervention: Sham infusion
Number of subjects: 16
Study 32706285 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental bath wipes containing silver
Number of subjects: 127
Study 32706285 — intervention group
Group type: COMPARATOR
Intervention: Standard bath wipes containing soap
Number of subjects: 127
Study 34427115 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab (Jemperli), administered intravenously
Number of subjects: 0
Study 34427115 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab (Jemperli)
Number of subjects: 0
Study 36328655 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 13026
Study 36328655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13026
Study 36497688 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum Transcranial Pulse Stimulation (TPS)
Number of subjects: 34
Study 36497688 — intervention group
Group type: COMPARATOR
Intervention: Sham Transcranial Pulse Stimulation (TPS)
Number of subjects: 34
Study 34064370 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral accentuated eccentric loading (AEL) in the leg press exercise of the dominant leg, performed twice a week for 10 weeks.
Number of subjects: 69
Study 34064370 — intervention group
Group type: COMPARATOR
Intervention: Control group without training.
Number of subjects: 69
Study 32616238 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet + 2% MOS meal
Number of subjects: 225
Study 32616238 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet + 4% MOS meal
Number of subjects: 225
Study 32616238 — intervention group
Group type: COMPARATOR
Intervention: Control (CON), basal diet + 0% MOS meal
Number of subjects: 225
Study 32616238 — intervention group
Group type: EXPERIMENTAL
Intervention: MOS diets (2% and 4%)
Number of subjects: 225
Study 34848566 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g intravenous tranexamic acid over 10 min, followed by 1 g intravenous tranexamic acid over 8 hours
Number of subjects: 180
Study 34848566 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 180
Study 35507907 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS Empress (n=20 teeth)
Number of subjects: 30
Study 35507907 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Z250 (n=20 teeth)
Number of subjects: 30
Study 35507907 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS Empress
Number of subjects: 30
Study 35507907 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Z250
Number of subjects: 30
Study 35877105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular alteplase
Number of subjects: 715
Study 35877105 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic thrombolysis of hematoma
Number of subjects: 715
Study 35877105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 715
Study 35877105 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 715
Study 35877105 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolution of ICH by day 30
Number of subjects: 715
Study 35877105 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolution of IVH by day 30
Number of subjects: 715
Study 35877105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral perfusion pressure less than 60 mm Hg
Number of subjects: 715
Study 35877105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis
Number of subjects: 715
Study 35877105 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged mechanical ventilation
Number of subjects: 715
Study 35877105 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for intracranial pressure monitoring
Number of subjects: 715
Study 35010653 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning intake of creatine
Number of subjects: 14
Study 35010653 — intervention group
Group type: COMPARATOR
Intervention: Evening intake of creatine
Number of subjects: 14
Study 32388650 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal PEEP (median=10, range: 8-14 cmH2O)
Number of subjects: 39
Study 32388650 — intervention group
Group type: COMPARATOR
Intervention: Standard PEEP (6 cmH2O)
Number of subjects: 39
Study 32162533 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in combination with BCG
Number of subjects: 0
Study 32162533 — intervention group
Group type: COMPARATOR
Intervention: BCG therapy
Number of subjects: 0
Study 35970327 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + brexpiprazole 2 mg (n = 486)
Number of subjects: 1256
Study 35970327 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + brexpiprazole 2–3 mg (n = 770)
Number of subjects: 1256
Study 34106630 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage (vibration and ring massage), once a day, 30 minutes per session, for 5 days, totaling 4 courses of treatment.
Number of subjects: 60
Study 34106630 — intervention group
Group type: COMPARATOR
Intervention: Spleen-invigorating bolus, orally, twice a day, 1 pill in the morning and 1 pill in the evening, for 5 days, totaling 4 courses of treatment.
Number of subjects: 60
Study 34106630 — intervention group
Group type: COMPARATOR
Intervention: Healthy group (no intervention).
Number of subjects: 60
Study 34106630 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI (Rs-fMRI) to observe BOLD signals in the brain, and MRS technology to observe GABA and 5-HT levels in the hypothalamus.
Number of subjects: 60
Study 34106630 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum analysis for CRH, ACTH, COR, GABA, NE, PGE2, and 5-HT levels.
Number of subjects: 60
Study 32839976 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Hz neurostimulation of the itching area through matrix electrodes (EG)
Number of subjects: 29
Study 32839976 — intervention group
Group type: COMPARATOR
Intervention: Placement of matrix electrodes without neurostimulation (CG)
Number of subjects: 29
Study 35038022 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 24 weeks (3 sessions/week)
Number of subjects: 27
Study 35038022 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Endurance Training (MIT) for 24 weeks (3 sessions/week)
Number of subjects: 27
Study 33262252 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - loading dose 1 g over 10 min, then 1 g infusion over 8 hours
Number of subjects: 1767
Study 33262252 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 1767
Study 33262252 — intervention group
Group type: COMPARATOR
Intervention: Post-randomisation scan status
Number of subjects: 1767
Study 34127294 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabies vaccine
Number of subjects: 546
Study 34127294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546
Study 33833190 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiGraph HRV protocol
Number of subjects: 64
Study 36281683 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromethylthionine mesylate 16 mg/day
Number of subjects: 545
Study 36281683 — intervention group
Group type: COMPARATOR
Intervention: Hydromethylthionine mesylate 8 mg/day
Number of subjects: 545
Study 36281683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 545
Study 34275972 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes codes alone
Number of subjects: 72
Study 34275972 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes codes and/or prescriptions
Number of subjects: 72
Study 34275972 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diabetes codes and prescriptions
Number of subjects: 72
Study 32556324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry cupping therapy
Number of subjects: 32
Study 32556324 — intervention group
Group type: COMPARATOR
Intervention: Sham cupping
Number of subjects: 32
Study 32556324 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no treatment)
Number of subjects: 32
Study 35347643 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Motivational Interviewing (TMI)
Number of subjects: 232
Study 33223374 — intervention group
Group type: EXPERIMENTAL
Intervention: Invisalign treatment for Class II malocclusion
Number of subjects: 40
Study 33223374 — intervention group
Group type: EXPERIMENTAL
Intervention: Invisalign treatment for Class I malocclusion
Number of subjects: 40
Study 33223374 — intervention group
Group type: EXPERIMENTAL
Intervention: Invisalign treatment
Number of subjects: 40
Study 33027748 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
Number of subjects: 0
Study 33027748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35797790 — intervention group
Group type: EXPERIMENTAL
Intervention: New 'one-stop-shop' scan protocol combining brain CTP and head-and-neck CTA
Number of subjects: 60
Study 35797790 — intervention group
Group type: COMPARATOR
Intervention: Traditional scan protocol with separate brain CTP and head-and-neck CT examination
Number of subjects: 60
Study 32371731 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine-alcohol solution
Number of subjects: 128
Study 32371731 — intervention group
Group type: COMPARATOR
Intervention: 10% povidone-iodine solution
Number of subjects: 128
Study 32371731 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 128
Study 34265814 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected (SS) cadence
Number of subjects: 44
Study 34265814 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 PU·min ‐1
Number of subjects: 44
Study 34265814 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing cadence
Number of subjects: 44
Study 33021670 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-specific, home-based strength, balance, and walking training supported by tailored motivational strategies
Number of subjects: 118
Study 33021670 — intervention group
Group type: COMPARATOR
Intervention: Placebo activity
Number of subjects: 118
Study 35631156 — intervention group
Group type: EXPERIMENTAL
Intervention: GTB1 (Lactiplantibacillus plantarum APsulloc 331261)
Number of subjects: 27
Study 35631156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 33736993 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified natural cycle FET (NC-FET)
Number of subjects: 98
Study 33736993 — intervention group
Group type: COMPARATOR
Intervention: Artificial cycle FET (AC-FET)
Number of subjects: 98
Study 36026477 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined maize porridge with [57Fe]-labeled crickets
Number of subjects: 20
Study 36026477 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined maize porridge with unlabeled crickets
Number of subjects: 20